dc.contributor.author | Manickavasagar, T | |
dc.contributor.author | Yuan, W | |
dc.contributor.author | Carreira, S | |
dc.contributor.author | Gurel, B | |
dc.contributor.author | Miranda, S | |
dc.contributor.author | Ferreira, A | |
dc.contributor.author | Crespo, M | |
dc.contributor.author | Riisnaes, R | |
dc.contributor.author | Baker, C | |
dc.contributor.author | O'Brien, M | |
dc.contributor.author | Bhosle, J | |
dc.contributor.author | Popat, S | |
dc.contributor.author | Banerji, U | |
dc.contributor.author | Lopez, J | |
dc.contributor.author | de Bono, J | |
dc.contributor.author | Minchom, A | |
dc.date.accessioned | 2021-06-03T09:39:46Z | |
dc.date.available | 2021-06-03T09:39:46Z | |
dc.date.issued | 2021-04-09 | |
dc.identifier | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000638291500001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=d4b848928d1c3e5c86d298abb68475f9 | |
dc.identifier | ARTN LMT48 | |
dc.identifier.citation | LUNG CANCER MANAGEMENT, 2021, pp. ? - ? (12) | |
dc.identifier.issn | 1758-1966 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4597 | |
dc.identifier.eissn | 1758-1974 | |
dc.identifier.doi | 10.2217/lmt-2020-0031 | |
dc.description.abstract | AIM: We explore HER3 expression in lung adenocarcinoma (adeno-NSCLC) and identify potential mechanisms of HER3 expression. MATERIALS & METHODS: Tumor samples from 45 patients with adeno-NSCLC were analyzed. HER3 and HER2 expression were identified using immunohistochemistry and bioinformatic interrogation of The Cancer Genome Atlas (TCGA). RESULTS: HER3 was highly expressed in 42.2% of cases. ERBB3 copy number did not account for HER3 overexpression. Bioinformatic analysis of TCGA demonstrated that MEK activity score (a surrogate of functional signaling) did not correlate with HER3 ligands. ERBB3 RNA expression levels were significantly correlated with MEK activity after adjusting for EGFR expression. CONCLUSION: HER3 expression is common and is a potential therapeutic target by virtue of frequent overexpression and functional downstream signaling. | |
dc.format.extent | ? - ? (12) | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | FUTURE MEDICINE LTD | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0 | |
dc.subject | Science & Technology | |
dc.subject | Life Sciences & Biomedicine | |
dc.subject | Respiratory System | |
dc.subject | ERBB3 | |
dc.subject | HER3 | |
dc.subject | MEK | |
dc.subject | NSCLC | |
dc.title | HER3 expression and MEK activation in non-small-cell lung carcinoma. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2021-02-22 | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.2217/lmt-2020-0031 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by-nc-nd/4.0 | |
rioxxterms.licenseref.startdate | 2021-04-09 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | LUNG CANCER MANAGEMENT | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Pharmacology – Adaptive Therapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.) | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Pharmacology – Adaptive Therapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.) | |
pubs.publication-status | Published | |
pubs.embargo.terms | Not known | |
icr.researchteam | Clinical Pharmacology – Adaptive Therapy | |
icr.researchteam | Thoracic Oncology | |
icr.researchteam | Clinical Pharmacology – Adaptive Therapy | |
icr.researchteam | Thoracic Oncology | |
dc.contributor.icrauthor | Carreira, Suzanne | |
dc.contributor.icrauthor | Gurel, Bora | |
dc.contributor.icrauthor | Miranda, Susana | |
dc.contributor.icrauthor | Banerji, Udai | |
dc.contributor.icrauthor | De Bono, Johann | |
dc.contributor.icrauthor | Minchom, Anna | |